Cephagenix was founded in February 2020, with the aim of identifying and developing new effective migraine treatments.
Cephagenix aims to develop first-in-class KATP channel inhibitors as an efficacious and safe treatment of migraine.
Cephagenix is a joint venture between JOHealth ApS and Saniona A/S.
